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ABSTRACT
Investigations in laboratory animals indicate
that certain drugs that influence specific neuro-
transmitters can have profound effects on the
recovery process. Even small doses of some
drugs given after brain injury facilitate recovery
while others are harmful. Preliminary clinical
studies suggest that the same drugs that enhance
recovery in laboratory animals (e.g.,
amphetamine) may have similar effects in
humans after stroke. In addition, some of the
drugs that impair recovery of function after
focal brain injury in laboratory animals (e.g.
haloperidol, benzodiazepines, clonidine,
prazosin, phenytoin) are commonly given to
stroke patients for coincident medical problems
and may interfere with functional recovery in
humans. Until the impact of pharmacologic
agents on the recovering brain is better
understood, the available data suggest that care
should be exercised in the selection of drugs used
in the treatment of the recovering stroke patient.
Pharmacologic enhancement of recovery after
focal brain injury may be possible in humans.
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INTRODUCTION
Stroke and traumatic brain injury are major
causes of neurologic disability. Although many
stroke survivors have significant deficits, most
recover some degree of function/53/. This recovery
can continue over a period of years in certain
individuals/6/; however, spontaneous improvement
is largely completed by one month after stroke
(Fig. 1)/53,114,124,139,188,189/. Traumatic brain
injury affects 200-400 persons per 100,000
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Fig. 1. Motor recovery after stroke. The motor deficits of
104 patients with ischemic stroke were measured
prospectively with the Fugl-Meyer Assessment.
Patients were stratified into groups based on the
initial severity of the motor deficit. Regardless of
initial severity, the most dramatic recovery
occurred over the first 30 days. Reproduced from
Duncan, Goldstein and Divine et al./53/.
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population in the United States/70/. Although most
of these individuals have only minor injuries and do
not come to medical attention/70/, moderate head
injury (Glasgow Coma Scale 9-12) affects 60-
75,000 cases per year /132/. Of patients with
moderate head trauma, two-thirds are moderately to
severely disabled 3 months after the injury/155/.
Because of the prevalence of stroke and
traumatic brain injury, therapies that improve
recovery would have significant medical, social and
economic importance. This review discusses recent
insights into the functional processes underlying
recovery that have led to the preliminary clinical
applications ofnew treatment strategies designed to
enhance function after brain injury.
RECOVERY AFTERFOCAL BRAIN INJURY
Biologic processes that influence functional
recovery after focal brain damage can be empirically
divided into two main, but interrelated, groups.
These groups of processes entail the resolution of
the pathologic sequellae of the injury and the
adaptive responses of brain tissue that was not
damaged by the primary lesion (Table 1). The
adaptive responses can be further divided into
rapidly and more slowly developing processes.
TABLE 1
Biologic processes influencing functional recovery after
focal brain damage
Resolution of pathologic sequellae
1. Cerebral edema
2. Diaschisis
3. Denervation supersensitivity
4. Rapid changes in dendritic spines
II. Adaptive responses
1. Rapid adaptive responses
Un-masking
Re-learning
2. Slow adaptive responses (neuronal
rearrangements)
Regeneration
Pruning
Collateral sprouting
Ingrowth
Pathologic sequellae
Cerebral edema commonly accompanies brain
injury. Its complex pathophysiology has been
extensively reviewed (see/112/). Cytotoxic cerebral
edema involves the accumulation of intracellular
fluid whereas vasogenic edema entails leakage of
proteins and fluid from damaged blood vessels (a
defect of the blood-brain barrier). Cerebral edema
may produce local functional depression in the area
immediately surrounding the primary area of injury.
Remote functional depression can be caused by
compression of distant normal structures. Clinical
worsening and spontaneous improvement in patients
after acute brain injury may be due, in part, to the
development and subsequent resolution of edema.
Diaschisis, a term originated by the German
pathologist Von Monakow/187/, refers to sudden
functional depression of brain regions distant from
the site of primary injury. Diaschisis has been
reviewed by Feeney and is discussed elsewhere in
this issue/57,58/. Diaschisis has been demonstrated
experimentally in a variety of laboratory animal
model systems /31,65,109,183/. In humans,
reductions of blood flow and metabolism following
hemispheric stroke have been demonstrated by
positron emission tomography in the non-injured
ipsilateral cerebral hemisphere, the contralateral
cerebral hemisphere, and the contralateral
cerebellum /68,118,133,182/. Crossed cerebellar-
cortical diaschisis occurs in patients with unilateral
cerebellar infarction /19/. Capsular or thalamic
stroke also can have remote effects on metabolism
in the cerebral cortex and cerebellum /142/. The
pathophysiologic mechanism underlying diaschisis is
not understood /31,58/. Depression of metabolic
activity in brain regions distant from the primary site
of injury might be a reflection of regional changes in
cerebral blood flow. Alternatively, decreased
regional cerebral blood flow may be a secondary
phenomenon reflecting locally depressed cerebral
metabolism. These remote areas of depressed
cerebral metabolic activity could result from injury
to excitatory projections from the injured region. It
has also been suggested that diaschisis could be
caused by the release of vasoactive or neuroactive
substances from the damaged brain/168/.
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As in the peripheral nervous system, lesions in
the central nervous system may also result in
enhanced responses of targets to neurotransmitters
(denervation supersensitivity) /40/. The potential
relationship of this phenomenon to behavioral
recovery has been extensively reviewed (see/67/).
Briefly, partial damage to the dendritic tree results
in an acute decrease in the amount of neuro-
transmitter available at the synapse. An up-
regulation of post-synaptic receptors ensues.
Subsequent presentation of a smaller amount of
neurotransmitter then results in an exaggerated
physiologic response that may restore function. A
variety of other short-term synaptic changes may
occur /199/ and rapid morphological changes in
dendritic spines have been observed in different
species under a variety of conditions/76,199/.
Rapid adaptive responses
Distinct from processes involved in the
resolution of the pathologic sequellae of brain
injury, adaptive responses refer to the mechanisms
by which uninjured brain assumes functions that
were previously performed by injured neurons.
Several theoretical types of adaptive responses may
occur. One hypothesis is that redundant neural
networks may perform functions lost due to brain
injury. This hypothesis was suggested by Lashley
/117/ and Luria /126,127/ and has also been
discussed as un-masking/192/. More recent studies
with positron emission tomography in human stroke
patients demonstrate metabolic changes that are
consistem with unmasking. In uninjured humans,
motor movement is associated with increases in
regional cerebral blood flow (rCBF) in a
circumscribed region in the contralateral primary
sensorimotor cortex. However, in patients
recovered from stroke that had resulted in limb
paresis, movement ofthe previously affected limb is
associated with significant changes in rCBF in
widespread areas of the brain including both
ipsilateral and contralateral sensorimotor cortex and
cerebellar hemispheres/32,196/.
A second general hypothesis is that the cellular
mechanisms that may be responsible for normal
learning might also underlie behavioral recovery
(e.g. recovery represents a type of relearning). The
best understood putative cellular mechanism of
learning and memory is long-term potentiation
(LTP) /14-16/. LTP has been described by
Collingridge and Bliss as a "kind of activity-
dependent change in synaptic efficacy that is
assumed to provide the physiological basis of
information storage in the brain" /37/. In the
hippocampal formation, LTP is induced by a single,
transient, high-frequency stimulation of excitatory
neural inputs. This produces an increase in synaptic
responses that can last for prolonged periods of
time/15,16/. LTP has been best characterized in the
hippocampal formation, but has also been
demonstrated in several other brain regions
including hypothalamus /3 8/, visual cortex/4,5/and
motor cortex/113/.
Slow adaptive responses
A variety of neuronal rearrangements occur after
many types of brain injuries/39,46,67,110,125,152,
153/. Some of these rearrangements would be
expected to be beneficial while others are
potentially maladaptive and could contribute to the
ultimate functional deficit. Davis has classified
neuronal rearrangements into four major groups
/46/. Regeneration refers to the regrowth of an
injured neuron’s axon to reinnervate the denervated
target. Axonal regeneration would be the ideal
rearrangement to restore function. Although
controversial and difficult to demonstrate,
functional regeneration of axons may occur in the
central nervous system/12,69/. Pruning occurs in
highly collateralized neurons (single neurons with
many axons). When one axon is injured, collateral
branches extend to reinnervate the target /166/.
Unlike regeneration, pruning has been clearly
demonstrated in the adult brain and should be a
beneficial adaptive rearrangement /73-75,91,92,
147/. Collateral sprouting, the most extensively
studied neuronal rearrangement, refers to neurite
outgrowth from an uninjured neuron in response to
damage to an adjacent fiber. Sprouting has been
demonstrated in the central nervous system/39/and
can result in the formation of electrophysiologically
functional synapses/176,185/. Collateral sprouting
may be maladaptive because it usually results in the
hyperinnervation of the target. Ingrowth is the
response of an uninjured nerve to a remote injury. A
foreign neuron grows to innervate a target in
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response to the loss of the targct’s normal
innervation. The most extensively studied example
of ingrowth is the expansion of sympathetic fibers
from surface blood vessels into the brain
parenchyma after certain lesions/43/. Sympathetic
ingrowth interferes with recovery after various
specific experimental lesions in laboratory animals
/93,94/.
DRUGS AND FUNCTIONAL RECOVERY:
FUNDAMENTAL STUDIES
Drugs can influence recovery through a variety
ofmechanisms affecting the resolution of pathologic
sequellae of brain injury as well as both rapid and
slow adaptive brain reslgonses. An individual drug
could impact on all of these processes. These drug
effects may be either beneficial or detrimental
(Table 2).
TABLE 2
Effects ofsome drugs on recovery
Transmitter/Drug Effect on Recovery
Norepinephrine +
Amphetamine +
Clonidine
Haloperidol
Prazosin
Propranolol 0
GABA
Diazepam
Muscimol
Phenytoin
Ro 15-1788 +
Acetylcholine +
Scopolamine
Glutamate
MK-801 -/0
"+" indicates a beneficial effe on recovery’,
"-" indicates a detrimental effect, and
"0" indicates no effect. Revised from
Goldstein/80/. See text for references.
Catecholamines
Amphetamine is among the most extensively
studied drugs with the capacity to facilitate recovery
atter focal brain injury. It was recognized as early as
1946 that treatment with amphetamine restored
righting and other postural activity in low
decerebrate cats/130/. Placing responses returned
in hemidecorticate and neodecorticate cats
following amphetamine administration/61,128,136/.
More recently, an enduring recovery of function has
been demonstrated in cats that had been subjected
to bilateral visual cortex ablations /62,106/. This
lesion results in a complete and permanent deficit of
stereopsis. Treatment with amphetamine, when
combined with visual experience, resulted in
recovery of binocular depth perception. Relearning
of a visual discrimination task in visually
decorticated rats is also facilitated by amphetamine
/25/.
Because motor function is a particularly
important determinant of physical function and
independence in activities of daily living after brain
injury in humans /119/, the impact of drugs on
motor recovery alter focal cortex injury has been
the subject of extensive laboratory investigations. A
sensorimotor cortex lesion in the rat does not result
in a dramatic motor deficit when the animals are
observed on a flat field, but becomes obvious when
the animals traverse a narrow elevated beam (beam-
walking ability) /29,129/. Feeney et al. devised a
simple system for grading this motor deficit and
found that a single dose of D-amphetamine
administered 24 hours following unilateral
sensorimotor cortex ablation accelerated the rate of
functional recovery /59,60/. Post-lesion treatment
with amphetamine also enhanced motor recovery in
cats with unilateral or bilateral frontal cortex
ablation/104,136,179/.
Understanding the pharmacologic mechanism of
amphetamine-facilitated recovery has been
hampered because the drug has diverse central and
peripheral effects. Systemic administration of
amphetamine may produce raised blood pressure
with reflex bradycardia, behavioral arousal and
hypermotility/197/. Dextroamphetamine also may
induce changes in regional cerebral blood flow and
metabolism/134,135/. Furthermore, amphetamine’s
central actions may be mediated through
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noradrenergic, dopaminergic, or serotonergic
neurons /72/. The pharmacologic and behavioral
effects of amphetamine are also dose dependent.
For example, the levels of norepinephrine in rat
brain are decreased when amphetamine is
administered in a relatively high dose. This effect is
most likely caused by depletion of granular amine
stores combined with an inhibition of the re-uptake
mechanism /72/. However, acute pharmacologic
effects ofthe drug may also be related to the release
of extragranular accumulations of catecholamines
/72/. In addition, amphetamine may induce a
disaggregation of brain polysomes thereby
influencing protein synthesis/138/. The dose-effect
curve for amphetamine-facilitated motor recovery in
rats formed an inverted ’U’ with a decline in
response at higher doses/80/. This decline is likely
due to amphetamine-induced stcrcotypies.
One strategy that has been employed to study
the pharmacologic basis of the amphetamine effect
has been to measure the impact of a series of
specific agonists and antagonists on functional
recovery. Coadministration of haloperidol blocks
amphetamine-promoted recovery /60,105/ and
halopcridol impairs motor recovery when given
alone /60/. Although haloperidol is a
butyrophenonc, in addition to its action as a
dopamine receptor antagonist, it has antagonist
effects at noradrcncrgic receptors /35,47,146/.
Other lines of evidence suggest that amphetamine-
promoted recovery of function is noradrcncrgically
mediated. Intraventricular /21/ or cerebellar /22/
infusions of norepinephrine facilitate recovery.
Intraventricular administration of dopamine in
combination with a dopamine-13-hydroxylase
inhibitor or dopamine alone had no effect /21/.
Treatment with a centrally acting Otl-adrencrgic
receptor antagonist (i.e., prazosin) interferes with
motor recovery /177,195/. Post-lesion systemic
administration of an ot2-adrencrgic receptor
antagonist (i.e., yohimbine, idazoxan) is beneficial
/79,89,177,178,195/, whereas the ct2-adrcnergic
receptor agonist clonidine impairs motor recovery
when given soon after brain injury /85/ and
reinstates motor deficits in recovered rats
/175,177,178,195/. Furthermore, prctrcatment with
the ncurotoxin DSP-4, a drug that selectively
depletes central norepinephrine, slows beam-
walking recovery /20,83/. Taken together, these
data suggest that amphetamine influences recovery
through its effects on central norepinephrine.
Although this work was largely carried out in rats
with aspiration lesions of the cerebral cortex, the
effect of noradrenergic agents on recovery is similar
in traumatic cerebral contusion and cortex infarction
injury models/49,66,107,108/.
GABA
Intracortical infusion of the inhibitory neuro-
transmitter 7-aminobutyric acid (GABA) increases
the hemiparesis produced by a small motor cortex
lesion in rats/23/.The deleterious effect ofGABA is
increased by the systemic administration of
phenytoin/24/, which may act through a GABA-
mediated mechanism /33/. The short-term
administration of diazepam, a benzodiazepine that
acts as an indirect GABA agonist, permanently
impedes recovery from the sensory asymmetry
caused by anteromedial neocortex damage in the rat
/163/. This long-term deleterious effect of diazepam
is mimicked by short-term infusion of the GABA
agonist, muscimol, into the sensorimotor cortex
adjacent to the lesion /100/ and is blocked by
coadministration of the benzodiazepine antagonist
Ro 15-1788 /97/. Ro 15-1788 alone produces a
transient facilitation ofrecovery/165/. Thus, GABA
or GABA agonists interfere with the recovery
process whereas GABA antagonists may be
beneficial.
Acetylcholine
In 1942 Ward and Kennard reported that
cholinergic agonists increased the rate of motor
recovery after motor cortex lesions in monkeys
/193/. The beneficial effects of cholinergic agonists
were blocked by administration of phenytoin/194/.
Recent data suggest that the anticholinergic drug,
scopolamine, interferes with motor recovery
following cortex infarction in rats/48/. As reviewed
by Feeney and Sutton, acetylcholine administration
appears to enhance recovery offunction/63/.
N-Methyl-D-aspartate (NMDA)
The availability of drugs which competitively
and non-competitively block specific subtypes ofthe
glutamate receptor has led to trials of these agents
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in experimental ischemia. The non-competitive
NMDA receptor antagonists MK-801 /13,26,115,
141,143,144/, dextromethorphan and dextrorphan
/170-172/, and the competitive NMDA receptor
antagonists CGS 19755 and CPP /17,27/ reduce
brain injury following focal ischemia. In contrast to
the potentially beneficial effect of MK-801 on the
local damage caused by ischemia, the administration
of this NMDA receptor antagonist reinstated
sensory deficits in rats that had recovered from
anteromedial frontal cortex injury/8/. The drug had
a slightly beneficial effect if given soon after the
brain injury. MK-801 had no effect on beam-
walking recovery in rats regardless of whether it
was administered to the animals soon ager the
injury or after spontaneous recovery was complete
/82/.
Growth factors/transplants
The use of growth factors to improve functional
outcome following brain injury is the topic for a
separate review (see /121/). There are a large
number of substances that can promote neuronal
survival or growth /121/. Treatment with nerve
growth factor (NGF), one of the first of these
substances identified, improves spatial learning
following nucleus basalis magnocellularis lesions in
rats/131/and prevents neuronal death alter brain
trauma /116/. Although originally considered a
neuronotrophic factor, GM1 ganglioside may have
several mechanisms of action /30,54/. Laboratory
studies suggest that post lesion administration of
gangliosides may improve functional outcome
/140,158,159/.
An extensive literature is available that provides
evidence for successful structural and functional
graRs of homotypic fetal brain tissue (see/184/).
For example, fetal neurons grained to the brains of
adult rats with ischemic lesions of the hippocampus
become structurally incorporated and establish
connections with the host brain/184/. Intracerebral
chromaffin cell autograts accelerate functional
recovery in adult cats with unilateral frontal cortex
ablation/180/.
DRUGS AND FUNCTIONAL RECOVERY:
MECHANISMS
It is logical that slow adaptive responses to
injury such as certain neuronal rearrangements
could result in a functional reorganization of the
brain that leads to behavioral recovery. However,
drugs such as amphetamine have acute, but
enduring effects on recovery. In the case of motor
function after sensorimotor cortex injury, enhanced
recovery occurs within one hour of amphetamine
administration with the effect persisting long ager
the drug has been metabolized /60/. Although
several general hypotheses have been offered, the
cellular mechanisms underlying these relatively
rapid drug effects remain largely speculative. Drugs
that influence the release or action of central
neurotransmitters could have an impact on both the
pathologic sequellae and rapid responses to brain
injury in a temporal frame consistent with
behavioral observations.
Potential drug effects on pathologic sequellae of brain
injury
It has been proposed that drugs such as
amphetamine may accelerate the resolution of
diaschisis and thereby facilitate the functional
recovery. As discussed by Feeney previously/57,65/
and elsewhere in this issue, there is considerable
experimental evidence in support of this general
hypothesis. Exogenous manipulation of the relative
levels of central neurotransmitters could also
influence the behavioral effects of post-synaptic
denervation supersensitivity or impact on the
resolution of cerebral edema.
Potential drug effects on rapid adaptive responses to
brain injury
Understanding the mechanisms of drug effects
on rapid adaptive responses is complicated because
their impacts may vary depending upon the nature
and location of the injury, the specific behavior
being measured and the timing of drug
administration. Amphetamine administration
improved motor outcome aider focal cortex injury
from an aspiration lesion/60,80/, cerebral contusion
/64/and focal infarction/49,107,108,160/, but had
no effect on spatial memory impaired after transient
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global ischemia /36/. The administration of
pentylenetrazol (PTZ) facilitated recovery from the
sensory asymmetry which resulted from unilateral
sensorimotor cortex injury in the rat /98,99/.
However, PTZ had no effect on motor recovery in
these same rats. The potential impact of lesion
location and pathophysiologic mechanism is
exemplified by the effects of the anticholinergic
scopolamine. Treatment with scopolamine
accelerated recovery of consciousness following
closed head injury in rats /95/. In contrast,
scopolamine interfered with motor recovery
following unilateral infarction of the rat
sensorimotor cortex /48/. The timing of drug
administration with respect to the injury may also be
critical. The detrimental effect of diazepam on
recovery from the sensory asymmetry following
unilateral anteromedial cortex damage in the rat
decreased as time between the injury and drug
administration increased /98/. MK-801 had a
slightly beneficial effect on sensory function in rats
if given soon after cortex injury, but was
detrimental ifgiven to recovered animals/8/.
Despite these complexities, several hypotheses
have been offered to explain drug effects on
recovery based on their impacts on potential rapid
adaptive brain responses. One hypothesis is that
certain drugs might facilitate the use of alternative
neural networks to perform functions lost due to
brain injury (un-masking). Treatment with stimulant
drugs such as amphetamine may promote the use of
alternative pathways by increasing the size of the
cortical receptive field responding to specific
peripheral stimuli in rats with cortex injury /49/.
Depressants (i.e., GABA or GABA agonists) could
interfere with this process and would be expected to
be detrimental/165/. The expected effects of drugs
on the resolution of diaschisis /57/ would be similar
to their effects on un-masking.
As discussed above, another hypothesis is that
the cellular mechanisms that underlie behavioral
recovery may also be responsible for normal
learning. This re-learning hypothesis is particularly
intriguing because both pre- and post-lesion
experience can have an important effect on recovery
/86,96,173,174/and because the impact of certain
drugs such as amphetamine is dependent on
concomitant task-specific experience/60,62,86,87,
96,104,174/. The best understood putative cellular
mechanism of learning and memory is long-term
potentiation (LTP) /16/. Catecholamines influence
the induction of LTP /103/ and have been
implicated in learning and memory /56,161,169/.
The administration of amphetamine both facilitates
the development of LTP in a dose dependent
manner/78/and enhances memory retrieval/2/. The
impact of other classes of drugs on recovery may
also be predicted based on their effects on the
induction of LTP/80/. For example, stimulation of
inhibitory GABAergic inputs to the hippocampal
formation/50,51/as well as the administration of
indirect GABA agonists (e.g., benzodiazepines)
/154,162/ suppress the induction of LTP. The
administration of benzodiazepines impairs learning
and memory/123,156/and they are detrimental if
given during the recovery period. Acetylcholine
would be expected to facilitate the induction ofLTP
by suppressing voltage-activated potassium cond-
uctance /37/. Activation of the muscarinic
cholinergic receptor facilitates the induction ofLTP
in the rat dentate gyrus/28/. Anticholinergics are
potent amnestic agents and impair motor recovery
after cortex injury.
Despite the attractiveness of the re-learning
hypothesis, it is clear that the effects of all drugs on
recovery cannot by predicted solely on the basis of
their impact on the induction of LTP. For example,
13-adrenergic receptor antagonists interfere with
LTP induction/44,45/. However, propranolol has
no effect on motor recovery aer sensorimotor
cortex injury /66/. The development of LTP is
mediated, at least in part, by theNMDA sub-type of
glutamate receptor/37,181,198/. The administration
ofNMDA receptor antagonists blocks the induction
of LTP, disrupts learning and memory/11,90,137/
and therefore would be expected to be particularly
harmful during recovery. The administration of the
NMDA receptor antagonist MK-801 reinstated
sensory deficits in rats that had recovered from
anteromedial frontal cortex injury/8/. However, as
discussed above, we recently completed a series of
experiments in which we were unable to
demonstrate any effect of the MK-801 on beam-
walking recovery after unilateral sensorimotor
cortex suction-ablation lesions in the rat/82/.
In summary, no single hypothesis is consistent
with all of the available behavioral data. The effects
of drugs on the recovery process are complex and
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could have an impact on a variety of pathologic
sequellae and rapid adaptive responses.
Potential drug effects on slow adaptive responses to
brain injury
Because the acute effects of certain drugs on
behavioral recovery are long-lasting, the relatively
rapidly developing physiologic effects must result in
more permanent changes in neurons and their
connections. Tissue injury can lead to activity-
dependent, neuropeptide-mediated neuronal
plasticity/52/. Neurotransmitters can have dramatic
effects on neurite growth cone development and
neurite elongation in vitro and on neural
development in vivo (see /122/). In this regard,
norepinephrine has been implicated in trophie
changes in the central nervous system. The
importance of norepinephrine in cortical plasticity
was demonstrated by Kasamatsu and coworkers in a
classic series of experiments /111/. These
investigators used changes in visual cortex ocular
dominance that followed brief monocular
deprivation as an index of cortical plasticity. Local
perfusion of 6-hydroxydopamine blocked the effects
of monocular light deprivation in kittens. Local
infusion of norepinephrine reinstated plasticity in
animals that were no longer sensitive to visual
deprivation. Norepinephrine released in the cerebral
cortex from locus coemleus projection fibers has
been suggested to lead to synaptic plasticity that
may encode learning/42/.
In contrast to the effects of norepinephrine,
Schallert and coworkers have found that chronic
administration of diazepam after anteromedial
cortex injury in the rat has significant detrimental
effects on subcortical structures receiving
projections from the damaged regions /165/. The
striatum was smaller and substantia nigra pars
retieulata neuronal loss was greater ipsilateral to the
cortex lesion in diazepam-treated animals/164,167/.
Thus, both norepinephrine and GABA (in addition
to a variety of other neurotransmitters/122/) may
influence both rapid and longer-term adaptive
responses to brain injury.
I)RUGS ANI) FUNCTIONAL RECOVERY:
CLINICAL STUI)IES
The use of drugs to improve recovery after brain
injury in humans had been attempted as early as the
1940s. More recent preliminary clinical studies
indicate that many of the same drugs that influence
recovery in laboratory animals have similar effects
on recovery in humans.
Amphetamine facilitated recovery in humans
Anecdotal reports indicate that treatment with
amphetamine improves cognitive function in young
adults with post-traumatic organic brain syndrome
/55,120/. Motivation in elderly patients refractory to
rehabilitation procedures also improves with
amphetamine treatment/34/. These effects are likely
due to the stimulant effects of the drug. However,
several other anecdotal reports and small controlled
trials suggest that treatment with amphetamine may
enhance functional recovery after focal brain injury
under certain conditions.
A small prospective, double-blind study was
carried out to determine whether amphetamine-
facilitated motor recovery occurs in humans aer
stroke /41/. The study was carefully designed to
simulate the paradigm used in the laboratory
experimental studies. A group of eight patients with
stable motor deficits within 10 days of ischemic
stroke were randomized to receive either a single
dose of amphetamine or placebo. Motor function
was measured with a reliable and validated scale,
the Fugl-Meyer Assessment/71/. Within three hours
of drug administration, all of the patients underwent
intensive physical therapy (i.e., drug administration
was coupled with task-specific experience). The
following day, the patients’ abilities to use their
affected limbs were reassessed. Overall, the
amphetamine-treated group had a significant
improvement in motor performance while there was
little change in the placebo-treated group (Fig. 2).
However, because this study involved only a small
group of highly selected patients, the results may
not be applicable to stroke patients with other types
of deficits. Because only short-term motor recovery
was measured, the longer-term efficacy of
amphetamine treatment is unknown. Until recently,
this study provided some ofthe only controlled data
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of a beneficial effect of amphetamine treatment on
motor recovery in humans.
Borueki and colleagues presented a preliminary
report of a double-blind, placebo-controlled study
designed to determine whether treatment with
amphetamine would enhance motor recovery in
patients undergoing inpatient stroke rehabilitation
/18/. Five patients were treated with amphetamine
and five received a placebo daily for 17 days with a
final assessment one week after the last day of drug
administration. The effect on motor performance
was measured with the Fugl-Meyer Assessment.
Although the final motor score was higher in
amphetamine-treated patients (70_+16 vs. 37__7), the
difference was not statistically significant. In
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Fig. 2:
Placebo Amphetamine
p<.05 Wilcoxon Rank Sum
Amphetamine and motor recovery after stroke. In a
double blind trial, eight patients with stable motor
deficits were randomized to receive a single dose of
10 mg of D-amphetamine or placebo followed by
physical therapy within 10 days of ischemic stroke.
The differences in Fugl-Meyer scores between
baseline and 24 hours after treatment for the
amphetamine-treated stroke patients and controls
are shown. See text for details. Modified from
Crisostomo et al. /41/.
contrast to the prior trial, this study included a more
heterogeneous group of stroke patients treated with
amphetamine or placebo beginning a longer period
of time after stroke. Importantly, it is uncertain
whether the patients received physical therapy in
conjunction with drug administration.
A second double-blind, placebo-controlled trial
of the effects of amphetamine on motor recovery in
rehabilitation patients has recently been performed
/190/. This study also included five amphetamine-
treated and five placebo-treated patients. Drug or
placebo was given once every 4 days for 10 sessions
beginning 15 to 30 days after stroke. Each dose was
given in conjunction with a session of intensive
physical therapy. Motor function was again
measured with the Fugl-Meyer Assessment with the
final evaluation one week after the last dose.
Patients treated with amphetamine had significantly
greater improvements in motor scores compared to
placebo-treated patients (median change in Fugl-
Meyer score of26 vs 13 points, p=0.047). Although
preliminary, these results suggest that amphetamine
may enhance motor recovery in human stroke
patients when drug administration is combined with
task-relevant experience.
Speech pathologists have been particularly
interested in studying the effects of drugs on
language recovery after stroke. Preliminary studies
indicate that the administration of bromocriptine
improves fluency in certain aphasics/1,7,157/and
that treatment with amphetamine may accelerate
recovery from aphasia in stroke patients/102/. A
larger feasibility study ofthe effects of amphetamine
on language recovery after stroke was recently
carried out (Fig. 3)/191/. Six aphasic patients had
language function rated with the Porch Index of
Communicative Ability /148/ 10 to 30 days after
stroke. Based on this initial evaluation, 6 month
language scores were predicted for each patient. All
patients were then given 10 mg of D-amphetamine
followed by speech therapy every 4th day for 10
sessions. The patients’ actual scores alter 3 months
were then compared with their 6 month predicted
scores. Most patients achieved or exceeded their 6
month predicted scores by the time of the 3 month
evaluation. A randomized prospective trial is now
planned.
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Other drugs and recovery in humans
Early reports suggested that cholinergic agents
might facilitate recovery following brain injury in
humans /145,186/. However, much of the data
concerning the impact of cholinergic drugs on
recovery of function is old and inadequate by
current standards.
GMl-ganglioside has been the subject of clinical
trials for the treatment of patients with a variety of
neurologic disorders including a recent report of
100
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x
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3 MonthObserved
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Fig. 3: Amphetamine and language recovery after stroke.
Six aphasic patients had language function rated
with the Porch Index of Communicative Ability 10
to 30 days after stroke. Based on this initial
evaluation, 6 month language scores were predicted
for each patient. All patients were then given 10
mg of D-amphetamine followed by speech therapy
every 4th day for 10 sessions. The patients’ actual
scores at 3 months were then compared with their 6
month predicted scores. Most patients achieved or
exceeded their 6 month predicted scores by the
time of the 3 month evaluation. From Walker-
Batson et al. /191/.
benefit in individuals with spinal cord injury/77/.
Small trials in stroke patients suggest that the drug
may be of some benefit /3,9,10/. However, the
clinical significance of the reported effects in these
studies is unclear and one trial failed to demonstrate
any impact of the drug on recovery in stroke
patients /101/. The preliminary results of a large
clinical trial of GMl-ganglioside in the treatment of
patients with acute stroke have recently been
presented /161/.
"Deleterious" drugs after stroke
Although the previous discussion has focused on
the use of drugs to enhance recovery aider stroke, it
is important to recognize that the laboratory studies
suggest that some drugs may be detrimental (Table
2). We carried out a retrospective study of
physician prescribing patterns to determine what
drugs were used in the treatment of stroke patients
/84/. Over 80% of individuals were taking at least
one drug at the time of the stroke. Sixty-five
percent of patients were receiving multiple drugs.
Antihypertensives such as clonidine and prazosin
ana sedative hypnotics including benzodiazepines
were among the most commonly prescribed agents
(Fig. 4). Thus, several of the drugs that have
deleterious effects on recovery of function in
laboratory animals were commonly prescribed for
stroke patients for the treatment of coincident
medical conditions.
Determining whether the detrimental effects of
drugs anticipated from laboratory studies also occur
in humans recovering from stroke is difficult.
Largely anecdotal reports indicate that treatment
with haloperidol /63,149/ and certain antihyper-
tensives/150/may interfere with language recovery
in patients with aphasia following stroke. We
performed a retrospective study that tested the
hypothesis that drugs that are harmful during
recovery in laboratory animals would interfere with
motor recovery in human stroke patients /88/.
These potentially deleterious drugs included the
antihypertensives clonidine and prazosin,
neuroleptics, benzodiazepines, and phenytoin. The
motor recoveries of stroke patients who received
one or a combination of these drugs were compared
to the recoveries of a similar group of patients who
were not given any of these agents. The two groups
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of patients were similar with respect to a variety of
characteristics including age, blood pressure,
gender, and medical comorbidity. Motor function
was measured prospectively with the Fugl-Meyer
Assessment by observers who were blind to the
study hypothesis. Although the results of this study
need to be interpreted with caution, patients who
received one or a combination of the hypothesized
"detrimental" drugs at the time of stroke or during
the subsequent hospitalization had significantly
slower motor recoveries than a comparable group
of patients who did not receive one of these drugs
(Fig. 5). A multivariate analysis indicated a
significant effect of "drug group" after correcting
for the contributions of other variables including the
initial severity of the deficit.
Haloperidol
Phenytoin
Prazosin
Clonidine
Benzodiazepine
5 10 15
Percent of Patients (n=l 18)
Drugs prescribed after stroke. The drugs prescribed
for patients admitted to the hospital within 48
hours of a carotid distribution ischemic stroke were
recorded /84/. The percentages of patients
prescribed the indicated drugs are shown. This
study indicates that several of the drugs that have
deleterious effects on recovery of function in
laboratory animals are commonly prescribed for
stroke patients for the treatment of coincident
medical conditions. From Goldstein/81/.
Fig. 5:
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"Detrimental" drugs and motor recovery after
stroke. Motor function was measured prospectively
with the Fugl-Meyer Assessment in a cohort of
patients with ischemic stroke/71/. The medications
taken by these patients at the time of stroke or
during the subsequent hospitalization were
determined by review of their medical records. The
patients were then divided into two groups. One
group ("detrimental" drug group) had received one
or a combination of the drugs hypothesized to be
harmful based on laboratory animal experiments
(see text). The remaining patients, all ofwhom had
received at least one drug, were included in the
"neutral" drug group. Patients in the "detrimental"
drug group had greater initial deficits and
recovered motor function slower than patients in
the "neutral" drug group. Reproduced from
Goldstein et al. /88/.
SUMMARY
The development of an understanding of the
basic neurobiology underlying functional recovery
after focal brain injury is leading to new strategies
for the treatment of patients with stroke and
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traumatic brain injury. It is clear that certain drugs
influence behavioral recovery in laboratory animals
after brain injury. These drug effects can be either
beneficial or detrimental. Similar drug effects may
occur in humans. It is important to recognize that
some of the drugs used to treat coexisting medical
conditions may be harmful. Until we better
understand the true impact of these potentially
detrimental drugs on recovery, care should be
exercised in the use of these drugs in the treatment
of patients after brain injury. In combination with
new treatments designed to limit acute damage and
salvage injured neurons, new strategies aimed at
facilitating functional recovery offer the hope of
improved outcomes for the brain-injured patient.
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